



ELI LILLY AND COMPANY
Lilly Corporate Center
Indianapolis, Indiana 46285
(317) 276-2000

Legal Department - Patent Division

Facsimile Transmittal Sheet

Date:

February 17, 2000

Total Number of Pages: 3
(Including cover page)

To:

Examiner Moezie

FAX#:

703 305 7401

From:

Steven R. Davis

FAX#:

(317) 276-5172

COMMENTS:

Regarding 09/209,799

This facsimile message is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If you have received this facsimile in error, please notify us immediately by telephone (collect), and return the original message to us at the above address via U.S. Postal Service.

#7

Feb 11 - 18 out

p 7, 8, 20

7. Single crystals of a GLP-1 analog, a GLP-1 (derivative), a (DPP-IV protected GLP), a GLP-1 peptide analog or a biosynthetic GLP-1 analog, said crystals having tetragonal flat rod shaped or plate-like morphology.

- 7A. Single crystals of GLP-1 (7-37)OH or (an analog of) GLP-1 (7-37)OH having one amino acid substitution, said crystals having tetragonal flat rod shaped or plate-like morphology.

Support: Page 5, lines 12-15

- 7B. Single crystals of GLP-1 (7-37)OH or (an analog of) GLP-1 (7-37)OH having one amino acid substitution, said crystals having tetragonal flat rod shaped or plate-like morphology and said amino acid substitution being at position 8.

Support: Page 5, lines 12-15 and page 9, lines 13-18

- 7C. Single, substantially homogenous crystals of a DPP-IV protected GLP, said crystals having tetragonal flat rod shaped or plate-like morphology.

dipepti-
dyl-peptid-
ase -IV
p3

Support: Page 5, lines 12-15 and page 9, lines 13-18

- 7D. Single crystals of a DPP-IV protected GLP, said crystals having tetragonal flat rod shaped or plate-like morphology and wherein said DPP-IV protected GLP is a GLP analog having a single amino acid substitution at position 8.

incorrect
terminology
no dimensions
given

714
100. A composition comprising, single crystals of a GLP-1 analog, a GLP-1 derivative, a DPP-IV protected GLP, a GLP-1 peptide analog, or a biosynthetic GLP-1 analog, said crystals having tetragonal flat rod shaped or plate-like morphology.

101. The composition of Claim 100, said composition being substantially homogenous.